- Neuromod has announced 19 new clinical partnerships to increase access to the Lenire® tinnitus treatment device.
- Partnerships with clinics in Spain, Belgium, Switzerland, Austria, Italy, Ireland, and the UK brings the number of European locations where Lenire is available to 50.
- Lenire® was proven to provide long-term relief from tinnitus that sustains for at least 12-months after treatment concluded in 91% of patients in its second clinic trial.3,6
- 91.5% of 220 real world patients treated with tinnitus had a clinically meaningful reduction in tinnitus after treatment with Lenire finds peer-reviewed study.4,6
Neuromod Devices, the technology company that specialises in medical devices for tinnitus treatment, has announced 19 new clinical partnerships to expand the availability of the Lenire tinnitus treatment device in Europe.
This latest expansion will significantly increase the number of clinics providing Lenire across Europe. Countries include Ireland, Spain, Italy, Belgium, Switzerland, Austria, and the United Kingdom.
“Tinnitus is one of the largest unmet needs in hearing healthcare and the prevalence of tinnitus is growing worldwide,” said Dr. Ross O’Neill, Neuromod Devices Founder and CEO. “These partnerships ensure that European tinnitus patients have access to a proven tinnitus treatment option with guidance from leading tinnitus care professionals.”
Lenire Available in Leading Tinnitus Clinics
Tinnitus, commonly known as “ringing ears,” is a condition that causes the constant perception of noise with no source. Approximately 65 million people are living with tinnitus in Europe.1
Jordon Thompson, Partner at Harley Street Hearing & Musicians’ Hearing Services, a new clinical partner based in London, spoke about the impact that Lenire has had on the clinic’s tinnitus patients.
“Harley Street Hearing & Musicians’ Hearing Services has been supporting tinnitus patients for over 25 years,” said Jordon Thompson, Clinical Lead. “We introduced Lenire into our practice nearly a year ago, and with Neuromod’s support our team quickly built confidence in this advanced technology. We are already seeing successful outcomes that are helping patients manage tinnitus more effectively.”
Lenire Proven in Clinical Trials and with Real World Patients
Lenire® is a bimodal neuromodulation device which has been proven to provide long lasting relief from tinnitus. The device is proven in multiple large-scale clinical trials. Lenire treats tinnitus through a combination of auditory and tongue stimulation that retrains the brain to significantly reduce tinnitus focus.
Lenire has been proven safe and effective in clinical trials in three large-scale clinical trials that featured more than 600 patients.3,4,5,6,7
Lenire’s most recent clinical trial, TENT-A3, was a controlled clinical trial. TENT-A3 found Lenire was clinically superior to sound-only, the trial’s control, for the majority of patients with bothersome tinnitus. Results from TENT-A3 were published in Nature Communications Medicine.5,6
Results from Lenire’s second large-scale clinical trial, TENT-A2, were published in Nature – Scientific Reports. TENT-A2 showed 95% of treatment compliant patients reported tinnitus improvement. 91% of whom reported long-term relief that sustained for at least a year after treatment ended.3,6
Analysis of 220 real world Lenire patients further validated Lenire’s effectiveness as a tinnitus treatment device. The analysis, peer-reviewed and published paper in Nature Communications Medicine, showed that 91.5% of patients treated with Lenire had a clinically significant reduction in tinnitus after 12-weeks of treatment with Lenire.4,6
Lenire is now available through hearing and tinnitus care clinics across Europe. Tinnitus patients can find a nearby clinic, and book an appointment by visiting www.lenire.com/find-a-clinic.
About Neuromod
Founded in 2010, Neuromod Devices is a global medical technology company with offices in Ireland, Germany and America. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations.
The lead application of Neuromod’s technology is in the field of tinnitus. Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. For more information visit www.neuromod.com.
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in large-scale clinical trials.
Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Lenire has also received a De Novo Approval Grant by the US FDA. Further details about Lenire® including a list of providers can be found at www.lenire.com.
References
- Lancet Reg Health Eur.. 2021 Nov 4:12:100250. doi: 10.1016/j.lanepe.2021.100250. eCollection 2022 Jan.
- R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021), https://doi.org/10.1016/j.lanepe.2021.100250
- Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, https://www.nature.com/articles/s41598-022-13875-x (2022)
- Mc Mahan, E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3
- Boedts M, B. A., Khoo G, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a controlled pivotal trial. Nature communications (2024)
- As measured by Tinnitus Handicap Inventory (THI).
- Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)
